Mindfulness Walking Intervention to Enhance Resilience (iWalk)

Part of paid clinical trials in Urbana, Illinois.

Sponsor
University of Illinois at Urbana-Champaign
Study ID
NCT07285954
Status
Recruiting
Apply to this trial

Conditions

  • Adults
  • EEG
  • Mindfulness
  • Neurodegenerative Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Accepted

Interventions

  • iWalk Program — BEHAVIORAL
    A multi-component behavioral program integrating walking meditation, education, and group sessions to enhance resilience and stress regulation in adults with and without chronic conditions.

Study Details

This study is a randomized controlled trial of the walking meditation intervention (iWalk) program, a multi-component intervention integrating walking meditation, education, and group sessions designed to enhance resilience in individuals with multiple sclerosis (MS). The objectives are to evaluate: 1. Recruitment capability and retention rates, 2. Acceptability and adherence to the intervention, 3. Feasibility of assessment procedures, and 4. Preliminary effects on psychological, physiological, and behavioral outcomes.

Key Dates

Start date
Jun 1, 2025
Status verified
Dec 2025
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: iWalk Program
    This group receives the complete iWalk program.
  • Active Comparator: Education Only without Walking Mindfulness Practice
    This group receives only education part of the iWalk program without walking mindfulness sessions.
  • No Intervention: Control Group
    This group does not receive any intervention and are placed on a waiting list.

Primary Outcome Measure

Connor Davidson Resilience Scale for Adults (CD-RISC 25) [ Time Frame: The baseline means assessments done two weeks before the intervention start date. Post-intervention assessments will be conducted two weeks after the intervention. Follow-up 1 is 24 weeks from baseline, and follow-up 2 is 48 weeks from baseline. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Illinois Urbana-ChampaignUrbanaIllinois61801
Chung-Yi Chiu
[email protected]
217-244-6435
[email protected]
Chung-Yi Chiu, Ph.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Urbana, IL

By research site
University of Illinois Urbana-Champaign· Urbana, IL

Related Studies